PICC market seen reaching $1.32 billion by 2030

The global peripherally inserted central catheter market is projected to grow from $1.07 billion in 2025 to $1.32 billion by 2030, driven by rising chronic disease burden and broader use in hospitals, ambulatory surgical centers and home infusion. North America leads the market now, while Asia-Pacific is expected to grow fastest.

Why it matters: - PICCs are a core tool for long-term intravenous access in cancer care, infection treatment, nutrition support and other therapies. - Growth in chronic disease cases is expanding demand for devices that can support repeated drug delivery, fluids and blood draws. - The market outlook signals more use of power-injectable, multi-lumen and tip-placement-enabled systems in more care settings.

What happened: - The Business Research Company said the peripherally inserted central catheter market is expected to reach $1.07 billion in 2025 and $1.12 billion in 2026. - The firm projects the market will climb to $1.32 billion by 2030. - The forecast implies a 4.4% CAGR from 2025 to 2026 and a 4.3% CAGR through 2030. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The company published links to a free sample report and the full market report.

The details: - A PICC is a slender, flexible tube inserted into a peripheral vein, usually in the arm, and guided to a large vein near the heart. - The superior vena cava is the target location for the catheter tip. - PICCs are used to deliver chemotherapy, antibiotics, parenteral nutrition and other medications. - PICCs are also used for blood sampling. - Rising chronic disease prevalence is a major growth driver, including cancer, diabetes, hypertension, heart disease, respiratory conditions, arthritis and obesity. - Data released in January 2023 by the National Library of Medicine projected that Americans age 50 and older living with one or more chronic diseases will nearly double to 142.66 million by 2050 from 71.52 million in 2022. - Broader adoption of PICC lines in hospitals for chemotherapy and antibiotic administration is supporting demand. - Early clinical acceptance of single-lumen and double-lumen conventional kits is also contributing to growth. - Expansion of catheterization lab services is increasing vascular access capacity. - Increased use in inpatient and critical care environments is adding to procedure volume. - Demand is rising for power-injectable and multi-lumen PICC systems. - Tip-placement kits and navigation-assisted insertion tools are being used to improve procedural accuracy. - PICC use is expanding into home infusion, outpatient therapy, oncology nutrition support and chronic infection management. - Procedure volumes in ambulatory surgical centers are increasing. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast points to a market shifting from basic vascular access toward more specialized devices designed for complex therapy needs. - Growth in outpatient and home-based care suggests providers are trying to move more treatment outside hospitals while preserving reliable access. - The regional split suggests the mature North American market remains dominant, but new volume growth is likely coming from Asia-Pacific.

What's next: - The Business Research Company said its 2026 reports will include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - Continued adoption of advanced PICC systems is expected as providers focus on reducing complications and improving long-term vascular access outcomes. - The company is directing readers to contact Saumya Sahay for more information.